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2. Summary 
 
Interleukin-22 (IL-22) is a unique cytokine produced by immune cells and acting 
exclusively on IL-22 receptor-1 (IL-22-R1) positive epithelial cells. IL-22 plays a central 
role in epithelial regeneration and contributes to pathogen clearance. In contrast, the 
proliferation enhancing effects of IL-22 may be used by cancer cells to promote and 
sustain their growth. This has been shown in genetically modified mouse strains with 
spontaneous development of colorectal cancer.  
 
The cellular sources of IL-22 in tumor tissue are not yet fully identified.  
 
In a pilot study with tumor tissue of patients with colorectal cancer, we could identify 
CD3+CD4+ T cells that produce IL-22. This confirms findings of other groups published in 
recent years. Peripheral T cells from healthy donors only contained low frequencies of 
IL-22 producing CD3+CD4+ cells. Upon stimulation, IL-22 induced STAT3 
phosphorylation and proliferation of human colon cancer cell lines. In one cell line, we 
could also show the induction of the cytokines IL-10 and VEGF. IL-22 suppressed IFN-γ-
induced synthesis of the chemokine CCL22 in HT29 cells while enhancing TNF-α-
induced expression of CCL22 in the same cell line. This indicates differential effects of 
IL-22 on IFN-γ- and TNF-α-signaling. IFN-γ as well as TNF-α led to IL-22-R1 
upregulation in human colon cancer cell lines. 
 
In summary, we find evidence that in tumor tissue CD3+ CD4+ T cells produce IL-22. 
IL-22 acts directly on cells of colorectal cancer cell lines. It enhances their proliferation. 
IL-22 presumable serves as a mediator in the genesis of colorectal cancer and a 
potential therapeutic target.
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 Zusammenfassung 
 
Interleukin-22 (IL-22) ist ein einzigartiges Zytokin welches von Immunzellen produziert 
wird und exklusiv auf IL-22-Rezeptor (IL-22-R1) positive epitheliale Zellen wirkt. IL-22 
spielt eine zentrale Rolle in der epithelialen Regeneration und trägt zur 
Pathogenbeseitigung bei. Im Gegensatz dazu könnten die Effekte von IL-22 von 
Krebszellen benutzt werden um ihr Wachstum zu fördern. Dies wurde in genetisch 
modifizieren Mauslinien mit spontaner Entwicklung von Kolonkarzinomen nachgewiesen.  
 
Die zellulären Quellen von IL-22 im Tumorgewebe sind noch nicht vollständig 
identifiziert. 
 
In einer Pilotstudie an Tumorgewebe von Patienten mit kolorektalem Karzinom konnten 
wir CD3+CD4+ T Zellen identifizieren, die IL-22 produzieren. Dies bestätigt in den letzten 
Jahren publizierte Befunde anderer Gruppen. Periphere T Zellen von gesunden 
Spendern enthielten nur geringe Frequenzen von IL-22 produzierenden CD3+CD4+  
T Zellen. Nach Stimulation induziert IL-22 in Zellen von humanen kolorektalen 
Karzinomzellllinen die Phosphorylierung von STAT3 und Proliferation. In einer Zelllinie 
konnten wir auch die Induktion der Zytokine IL-10 und VEGF nachweisen. IL-22 
unterdrückt IFN-γ-induzierte CCL22 Proteinexpression in HT29 Zellen wohingegen es 
die TNF-α-induzierte Expression von CCL22 in derselben Zelllinie verstärkt. Dies spricht 
für differenzielle Effekte von IL-22 auf die IFN-γ- und TNF-α-Signalwege. Sowohl IFN-γ 
als auch TNF-α führten zur Hochregulation von IL-22-R1 in Zellen von humanen 
kolorektalen Karzinomzellllinen. 
 
Zusammenfassend finden wir Hinweise, dass im Tumorgewebe IL-22 von CD3+ CD4+ 
T Zellen produziert wird. IL-22 wirkt direkt auf kolorektale Karzinomzellen. Es steigert 
deren Proliferation. IL-22 bildet vermutlich einen Mediator in der Genese von 
kolorektalen Karzinomen und ein potenzielles therapeutisches Target. 
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3. Introduction 
3.1. Physiology of interleukin-22 
 
Interleukin-22 (IL-22) is a member of the interleukin-10 (IL-10) family of cytokines which 
also comprises IL-10, IL-19, IL-20, IL-24, IL-26, IL-28α, IL-28β, and IL-29 (Wolk et al, 
2010). IL-22 was first described in 2000 as a secreted α-helical protein in IL-9-stimulated 
murine BW5147 T lymphoma cells (Dumoutier et al, 2000).  
 
 
3.1.1. Cellular sources of IL-22 
 
IL-22 is expressed by a number of immune cells of the innate and adaptive immune 
system. The cellular sources of IL-22 are immune cells. In general T cells and innate 
lymphoid cells are considered to be the major cellular sources of IL-22 (Sabat et al, 2014). 
CD4+ T cells, including Th-1 cells, Th-17 cells and Th-22 cells produce IL-22 (Duhen et al, 
2009; Witte et al, 2010; Wolk et al, 2002).  
 
Th-17 cells produce IL-22 as an effector cytokine together with IL-17 (Chung et al, 2006; 
Liang et al, 2006; Ouyang et al, 2008). The retinoic-acid-related orphan nuclear receptor 
RORγt is the master regulator of Th-17 cells (Ivanov et al, 2006). Among the factors that 
drive Th-17 differentiation and IL-17 expression, IL-6 and IL-23 induce IL-22 expression 
while transforming growth factor-β (TGF-β) antagonizes IL-22 induction (Rutz et al, 2011).  
 
Th-22 cells are defined as expressing the chemokine receptors CCR4, CCR6, CCR10 and 
producing IL-22 but not any other known T-helper-prototypical cytokine, such as IL-17 or 
IFN-γ. Th-22 cells have a high expression of the aryl hydrocarbon receptor (AHR) but a 
low expression of RORγt and T-bet (Duhen et al, 2009; Trifari et al, 2009). In vitro, Th-22 
cells may develop in interaction with plasmacytoid dendritic cells (pDCs) with IL-6 und 
TNF-α as driving factors (Duhen et al, 2009). Activation of the aryl hydrocarbon receptor 
(AHR) is important for IL-22 production in CD4+ memory T cells suggesting a role for AHR-
ligands in Th-22 polarization (Stockinger et al, 2009; Trifari et al, 2009; Veldhoen et al, 
2009). In addition, it has been reported that IL-23 stimulation is a prerequisite for the IL-22 
production of CD4+ T cells (Zheng et al, 2007). IL-1β has been described to further 
promote Th-22 differentiation (Ivanova & Orekhov, 2015).  
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In addition to CD4+ T cells, CD8+ T cells (Nograles et al, 2009) are also capable of 
producing IL-22 (Liu et al, 2011b; Ortega et al, 2009). Innate immune cells also belong to 
the IL-22 producers: IL-22 is expressed by certain natural killer (NK) cell subsets, natural 
killer T (NKT) cells (Goto et al, 2009), γδ T cells (Martin et al, 2009), LTi (lymphoid tissue 
inducer) cells (Sonnenberg et al, 2011) and LTi-like (lymphoid tissue-like inducer) cells 
(Takatori et al, 2009). 
 
Although IL-22 is produced by the above described immune cells it does not act on those. 
IL-22 is a unique cytokine, produced by immune cells, which does not act on cells of 
hematopoietic origin but on epithelial cells via the Janus kinase (JAK) - signal transducer 
and activators of transcription (STAT) pathway (Wolk et al, 2010). 
 
 
3.1.2. IL-22 receptor-1 and its signaling pathway 
 
IL-22 acts via a heterodimeric transmembrane receptor, composed of the IL-22-receptor-1 
(IL-22-R1) and the IL-10-receptor-2 (IL-10-R2) (Wu et al, 2008). The IL-22-R1 chain holds 
the docking site for STAT signal molecules. The IL-10-R2 component is ubiquitously 
expressed due to its function as part of several cytokine receptors. Cellular 
responsiveness to IL-22 is thus determined by the expression of IL-22-R1. IL-22-R1 is not 
expressed on cells of hematopoietic origin but on cells of epithelial and endothelial origin 
(Wolk et al, 2002; Wolk et al, 2004).  
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Figure 1: IL-22 signaling cascade. IL-22 signals via the activation of the Jak - STAT pathway. 
Receptor-associated tyrosine kinases Jak1 and Tyk2 are phosphorylated leading to 
phosphorylation of IL-22-R1 pre-associated STAT3. STAT3 dimerizes and translocates to the 
nucleus leading to transcription of target genes (modified from Wolk et al, 2010).  
 
IL-22 activates the JAK-STAT pathway. First phosphorylation of the receptor associated 
tyrosine kinases JAK1 and TYK2 takes place which in turn phosphorylate specific receptor 
tyrosine residues serving as docking sites for sarcoma homology 2 (SH2) domains of 
STAT3. Subsequently, receptor-docked STAT3, is phosphorylated itself, dimerizes and 
translocates into the nucleus. There, pSTAT3 can bind responsive elements and regulate 
gene expression (Lejeune et al, 2002).  
 
 
3.1.3. Physiological functions of IL-22  
 
Unlike most interleukins, IL-22 does not directly act on immune cells (Wolk et al, 2004), but 
regulates functions of cells of the body barriers (Sabat et al, 2014) where IL-22-R1 is 
expressed. The expression pattern identifies the main target cells: the digestive tract 
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
 12 
(pancreas, small intestine, liver, colon), the respiratory system (lung, trachea), kidney and 
skin (Wolk et al, 2004). 
 
The physiological function of IL-22 is to protect tissues from damage and to enhance their 
regeneration. In many of the above-mentioned cells IL-22 induces anti-microbial proteins 
and chemokines. Induction of an epithelial innate immune response directed against 
extracellular pathogens is one example of the protective function of IL-22. 
 
In the skin, IL-22 mainly targets keratinocytes (Wolk et al, 2009; Wolk et al, 2004). There, 
IL-22 signaling has been shown to control innate immunity by upregulating the expression 
of β-defensins 2 and 3 as well as the anti-microbial heterodimer S100A8/9 (Kolls et al, 
2008; Wolk et al, 2004; Wolk et al, 2006).  
 
In bronchial epithelial cells IL-22 upregulates G-CSF and antimicrobial proteins such as 
BD2, S100A7 and A100A12 and the chemokines CXCL1 and CXCL5. IL-22 promotes 
epithelial regeneration and reduction of K. pneumoniae growth (Aujla et al, 2008).  
 
IL-22 also acts on the gastrointestinal tract. In the pancreas, the organ with the highest 
IL-22-R1 expression, it has been shown that IL-22 induced osteopontin and pancreatitis-
associated protein (PAP) 1/RegIIIα (Aggarwal et al, 2001). In human intestinal epithelial 
cells IL-22 increased the expression of BD2 and IL-8 (Brand et al, 2006). The impact of IL-
22 in the defense against infections with bacteria of the intestinal tract has been shown in 
a number of studies: IL-22 induces the expression of anti-bacterial peptides namely: β-
defensins, RegIIIβ, and RegIIIγ, S100A7, S100A8 and S100A9 (Liang et al, 2006; Wolk et 
al, 2004; Wolk et al, 2006). The release of anti-bacterial peptides can be increased by the 
combination of IL-22 and IL-17 (Liang et al, 2006).  
 
 
3.1.4. Pathophysiological functions of IL-22 
 
IL-22 is upregulated in a number of chronic inflammatory and autoimmune diseases 
generating the hypothesis that IL-22 may be disease promoting in this context. The 
production of IL-22 by T cells may indicate that IL-22 is involved in the pathogenesis of T 
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
 13 
cell-mediated diseases such as psoriasis, rheumatoid arthritis (RA) or inflammatory bowel 
disease (IBD). 
 
The impact on keratinocytes is important in psoriasis and atopic skin pathogenesis where 
IL-22 has been found to be a key mediator. In atopic skin IL-22 has been found to be 
mainly produced by Th-22 cells (Nograles et al, 2009). In a psoriasis-like disease model it 
has been shown that upon treatment of mice with IL-22 neutralizing antibodies the 
expression of Th-17 cytokines was reduced as well as the recruitment of inflammatory 
infiltrates. In addition, this treatment prevented development of disease (Ma et al, 2008). In 
an imiquimod-induced mouse model of skin inflammation, skin lesions that are induced in 
wild-type mice were almost absent in IL-22-deficient mice or in mice treated with an IL-22 
blocking antibody (Van Belle et al, 2012). 
 
IL-22 is found in large quantities in the inflamed regions of the colonic mucosa in ulcerative 
colitis and Crohn’s disease, which are predisposing diseases for colorectal cancer (Andoh 
et al, 2005). In IBD CD4+ IL-22 expressing T cells have been shown to be present in the 
inflamed regions of the gut: In active Crohn’s disease and ulcerative colitis IL-22 is 
abundantly found in the submucosa or in the lamina propria, respectively (Andoh et al, 
2005; Brand et al, 2006). Furthermore, systemic IL-22 levels are increased in patients with 
Crohn’s disease (Wolk et al, 2007). One study showed that intestinal tissue from patients 
with IBD expressed significantly less AHR compared to controls. Conversely, there are 
experimental data that IL-22 can protect mice from IBD. This protection was mediated by 
CD4 T cells and IL-22 expressing NK cells (Zenewicz et al, 2008). In a mouse model it has 
been shown that AHR induced IL-22 and inhibited inflammation in the gastrointestinal tract 
(Monteleone et al, 2011). 
 
Th-22 cells are increased in the peripheral blood of patients suffering from rheumatoid 
arthritis (RA) and levels of IL-22 are increased in their plasma, which correlates with 
disease activity (da Rocha et al, 2012; Leipe et al, 2011; Zhang et al, 2011b; Zhang et al, 
2012a). Fibroblasts from patients with RA that show high concentrations of IL-22 increased 
proliferation and the release of CCL2, which attracts monocytes (Ikeuchi et al, 2005). 
Further, IL-22 deficient mice showed a less severe form of arthritis as compared to wild-
type mice, indicating the disease-promoting role of IL-22 (Geboes et al, 2009). 
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3.1.5. Influence of cyokines on IL-22 signaling  
 
IL-22 is generally secreted with other cytokines. IL-22 effects as well as IL-22 expression 
are influenced by other cytokines like IFN-α, IFN-γ, TNF-α and IL-17 (Eyerich et al, 2009; 
Guilloteau et al, 2010; Liang et al, 2006; Pennino et al, 2013). 
 
IL-22 can decrease the responsiveness of epithelial cells to T cell–mediated cytotoxicity by 
counteracting the IFN-γ –induced expression of MHC-I (Pennino et al, 2013). IFN-α, IFN-γ 
and TNF-α induce increased responsiveness of keratinocytes towards IL-22 by 
upregulation of IL-22-R1 and IL-10-R2 (Kunz et al, 2006; Tohyama et al, 2012). 
 
Figure 2: Crosstalk of IL-22 and IFN-γ in the context of effects on epithelial cells. IFN-γ 
induces chemokines in epithelial and cancer cells, upregulates MHC-I and IL-22-R1 (Kunz et al, 
2006; Pennino et al, 2013). IL-22 antagonizes chemokine upregulation and upregulation of MHC-I 
by IFN-γ (Pennino et al, 2013). Green arrows indicate effects of IFN- γ, red - indicate antagonistic 
effects of IL-22. 
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Figure 3: Crosstalk of IL-22 and TNF-α in the context of effects on epithelial cells. Stimulation 
leads to the upregulation of IL-22-R1(Wolk et al, 2009; Wolk et al, 2004). TNF-α upregulates 
complement factors C1r and C1s, peptides S100A7 and HBD-2 and chemokines CXCL-9, CXCL-10 
and CXCL-11 (Eyerich et al, 2011). These effects are further promoted by IL-22. Green arrows 
indicate effects of TNF-a and red + indicate synergistic effects of IL-22. 
 
 
IL-22 and TNF-α are both released by Th-22 cells (Eyerich et al, 2009). IL-22 enhances 
TNF-α-induced secretion of complement factors C1r and C1s, peptides S100A7 and HBD-
2 and chemokines CXCL-9, CXCL-10 and CXCL-11 (Eyerich et al, 2011). Expression of 
IL-22-R1 in both keratinocytes and dermal fibroblasts is induced by TNF-α (Wolk et al, 
2009; Wolk et al, 2004). In keratinocytes, IL-22 may also synergize with IL-17 and IFN-γ in 
inducing keratin 17 expression which indicates that IL-22 is involved in a positive feedback 
loop where keratin 17 induces the proliferation and activation of T cells (Zhang et al, 
2012b). 
 
One study showed that the function of IL-22 in a bleomycin-induced lung inflammation 
model differed in the presence or absence of IL-17. In the presence of IL-17, IL-22 led to 
more inflammation whereas in the absence of IL-17, IL-22 exerted tissue-protective 
functions (Sonnenberg et al, 2010).  
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3.1.6. Role of IL-22 in carcinogenesis 
 
The proliferative, tissue regenerating and pro-inflammatory properties of IL-22 raised the 
question of a potential involvement in cancer of this particular cytokine where its effects 
may be tumor-promoting.  
 
Table 1: Overview of literature connected to the role of IL-22 in cancer 
Cancer type Key messages of publication  
Lymphoma • Anaplastic large cell lymphoma shows aberrant expression of  
IL-22-R1 (Bard et al, 2008) as well as mantle cell lymphoma 
(Gelebart et al, 2011)  
• IL-22 stimulation of mantle cell lymphoma cell lines leads to 
increase of STAT3 activation and cell proliferation (Gelebart et al, 
2011)  
• Patients suffering from cutaneous T cell lymphoma show 
increased levels of IL-22 in lesional skin, elevate IL-22 serum levels 
correlate with severity of disease (Miyagaki et al, 2011) 
Gastric  
cancer 
• Increased circulating Th-22 and Th17 cells of patients are 
associated with tumor progression (Liu et al, 2012) 
• Increased intratumoral CD4+IL-22+ T cells and Th-22 cells are 
linked to tumor progression and lower patient survival (Zhuang et al, 
2012) 
• •         IL-22 produced by cancer-associated fibroblasts promotes 
cancer cell invasion (Fukui et al, 2014)   
Pancreatic 
cancer  
• IL-22 stimulated production of vascular endothelial growth 
factor (VEGF) and anti-apoptotic proteins (Curd et al, 2012). 
• Frequencies of CD4+IL-22+ cells and Th-22 cells were 
significantly increased in pancreatic cancer tissue compared to 
peripheral blood and healthy controls, intratumoral IL-22 levels and 
frequencies of Th-22 and CD4+ IL-22-producing cells has been linked 
to progression of disease (Xu et al, 2014) 
• High expression of IL-22 and IL-22-R is linked to poor patient 
prognosis (Wen et al, 2014) 
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Hepatocellular 
carcinoma  
 
 
• IL-22 in the tumor microenvironment, leads to increased 
growth, inhibition of apoptosis and promotion of metastases (Jiang et 
al, 2011) 
• Th-22 are associated with heptatocelluar carcinoma 
development (Qin et al, 2014) 
• IL-22 serum levels are a negative prognostic factor (Waidmann 
et al, 2014) 
Renal cancer • IL-22 dose-dependently suppresses renal cell carcinoma cells 
in vitro and induced growth inhibition of renal carcinoma cell-bearing 
mouse xenografts (Zhang et al, 2011a) 
Kaposi  
sarcoma 
• IL-22-R1 transcript levels are downregulated in Kaposi’s 
Sarcoma (Su et al, 2011) 
Lung cancer • The number of IL-22 producing Th-22 cells is increased in 
malignant pleural effusion (Ye et al, 2012). 
• •         Autocrine production of IL-22 may contribute to human lung 
cancer cell survival and resistance to chemotherapy through the 
upregulation of anti-apoptotic proteins (Zhang et al, 2008) 
• •           IL-22 was frequently expressed in human lung cancer tissue 
(Kobold et al, 2013) 
Skin cancer • Proliferation and migration of human skin basal cell 
carcinoma and squamous-cell carcinoma cell were increased by IL-
22, IL-22 induced STAT3 pathway and the antiapoptotic AKT 
protein, IL-22 enhanced tumor growth in nude mice injected with 
basal cell carcinoma cell lines (Nardinocchi et al, 2015) 
 
 
3.1.7. Role of IL-22 in colorectal cancer development 
 
Chronic mucosal inflammation predisposes patients to colorectal cancer development 
(Grivennikov et al, 2010). Patients suffering from ulcerative colitis and Crohn’s disease 
have a higher risk of developing colorectal cancer (Bernstein et al, 2001; Schottenfeld & 
Beebe-Dimmer, 2006). However, it is still poorly understood what type of immune cells and 
cytokines trigger the development from chronic inflammation to colorectal cancer. IL-22 is 
considered to play a crucial role in this process (Kirchberger et al, 2013).  
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
 18 
Experimental models of inflammation-associated colorectal cancer development suggest 
that inflammatory cell-derived cytokines (including IL-22) directly or indirectly stimulate the 
growth of cancer cells (Grivennikov et al, 2009; Huber et al, 2012; Hyun et al, 2012; 
Kirchberger et al, 2013). IL-22 seems to drive the development of colorectal cancer via the 
activation of STAT3 (Lim & Savan, 2014). Forced expression of IL-22 using retroviral 
transduction of Colon-26 carcinoma cell lines had no impact on tumor growth or 
metastasis but prolonged survival of inoculated mice (Nagakawa et al, 2004). Another 
study found an association of colorectal cancer and the human IL22 rs1179251 G allele 
with a 52 % increase in risk of developing colorectal cancer by individuals with at least one 
of these alleles (Thompson et al, 2010). IL-22 enhances iNOS expression and contributes 
to tumorigenesis in colorectal cancer (Takahashi et al, 1997; Ziesche et al, 2007). 
Oxidative activity mediated by IL-22 is required for activation of STAT3. An oxidative 
inflammatory microenvironment containing IL-22 increases the risk of tumor development 
(Bansal et al, 2013). 
 
Higher IL-22 serum levels are found in chemotherapy-resistant patients in contrast to 
chemotherapy-sensitive patients and IL-22 treatment of colorectal cancer cell lines 
enhances chemotherapy-resistance of these cancer cells (Wu et al, 2013). 
 
As a further line of evidence for the importance of IL-22 in colorectal cancer development, 
the lack of the natural antagonist to IL-22: IL-22-binding protein (IL-22BP) leads to 
enhanced colitis-associated colon carcinogenesis (Huber et al, 2012). In this setting, IL-22 
secretion is driven by infiltrating leukocytes, as peripheral leukocytes are weaker 
producers of IL-22. These IL-22 producing tumor-infiltrating lymphocytes enhance tumor 
growth and metastasis in a xenograft mouse model via STAT3 activation (Jiang et al, 
2013). In colorectal cancer, CD4+ T cells seem to be the main source of IL-22. IL-22 
promoted activation of STAT3 induces the methyltransferase DOT1L. The DOT1l complex 
in turn induces the core stem cell genes Sox2, Nanog and Pou5F1, leading to the 
conclusion that IL-22 promotes colorectal cancer stemness (Kryczek et al, 2014). 
 
Th-22 accumulation is linked to colorectal cancer development. IL-22 expression is 
significantly higher in tumor tissue than in peritumoral tissue (Huang et al, 2015).  
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3.2. Objectives 
 
Our group could previously show increased proliferation and STAT3 phosphorylation in 
human lung cancer cell lines upon IL-22 stimulation (Kobold et al, 2013). This study seeks 
to gain a better understanding of the effects of IL-22 and of IL-22 producing T cells on 
colorectal cancer cells.  
 
Tumor-infiltrating lymphocytes are important in colorectal cancer biology. Thereby, T cells 
producing tumor promoting IL-22 are significant players in this population. In addition, the 
exact impact of IL-22 at the cellular and sub cellular level in colorectal cancer is 
incompletely understood.  
 
To gain further understanding of IL-22 in colorectal cancer, IL-22-producing T cells will be 
analyzed: 
• Proportions of IL-22+ among Th-1, Th-17 and Th-22 cells in healthy human PBMC  
• Proportions of IL-22+ among Th-1, Th-17, Th-22 and CD8+IL-22+ T cells in tissue 
 taken from patients with cancer of the colon or of the rectum 
 
Additionally, the effect of IL-22 will be studied on human colorectal cancer cell lines: 
• Ability to phosphorylate STAT3 in colorectal cancer cells proliferation upon 
 IL-22 stimulation  
• Impact of IL-22 on cytokine release from colorectal cancer cells 
• Effect of IL-22 on IFN-γ as well as on TNF-α  
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4. Material and Methods 
4.1. Materials 
4.1.1. Chemicals and reagents 
 
Bovine serum albumine (BSA)    Sigma Aldrich, Steinheim, Germany 
Brefeldin A      Sigma Aldrich, Steinheim, Germany 
Dimethyl sulfoxide (DMSO)     Sigma Aldrich, Steinheim, Germany 
Dulbecco’s PBS (1x)      PAA, Pasching, Austria 
Ethylenediamine tetraacetic acid (EDTA)  Sigma Aldrich, Steinheim, Germany 
FACSFlow, FACSSafe     Becton Dickinson, San Jose, USA 
Fixable Viability Dye eFluor® 780    eBioscience 
Ionomycin      Sigma Aldrich, Steinheim, Germany 
Lysis buffer       Cell Signaling, USA 
Isopropanol (70 Vol %)     Apotheke Innenstadt, LMU Munich 
Phorbol 12-myristate 13-acetate (PMA)  Sigma Aldrich, Steinheim, Germany 
Propidium iodide     Sigma Aldrich, Steinheim, Germany 
Protease inhibitor cocktail     Sigma-Aldrich, Steinheim, Germany 
Rotiphorese® NF-Acrylamid/Bis-Lösung   Roth, Karlsruhe, Germany 
30 % (29:1)        
Trypan blue       Sigma Aldrich, Steinheim, Germany 
Tween® 20      Roth, Karlsruhe, Germany 
 
 
4.1.2. Cell culture reagents and media 
 
Dulbecco's modified Eagle´s medium  PAA, Pasching, Austria 
(DMEM) 
Fetal calf serum (FCS)     GibcoBRL (invitrogen), Karlsruhe,  
       Germany 
L-glutamine 200 mM      PAA, Pasching, Austria 
McCoy's 5A (modified)    Invitrogen, Carlsbad, USA 
NEM-NEAA (non-essential amino acids)   GibcoBRL (invitrogen), Karlsruhe, 
Germany 
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
 21 
Opti-MEM® I Reduced Serum Medium  GibcoBRL (invitrogen), Karlsruhe,  
       Germany 
1 x PBS      PAA, Pasching, Austria 
Phosphate-buffered saline (PBS)    PAA, Pasching, Austria 
Penicillin plus streptomycin (100 x)    PAA, Pasching, Austria 
Roswell Park Memorial Institute (RPMI)  PAA, Pasching, Austria 
1640 medium 
Sodium pyruvate      PAA, Pasching, Austria 
 
Disposable plastic equipment for cell culture experiments were purchased from Becton 
Dickinson (Heidelberg, Germany), Eppendorf (Hamburg, Germany), Falcon (Heidelberg, 
Germany), Greiner (Frickenhausen, Germany) or Sarstedt (Numbrecht, Germany). 
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4.1.3. Western blot buffers 
 
Table 2: Western blot buffers 
Separating gel buffer (4-fold) pH 8.5 
 
600 ml H2O 
182 g tris hydrochloride   
HCl to pH 8.8  
4 g SDS 
 
Stacking gel buffer (4-fold) pH 6.8 
 
300 ml H2O 
30.25 g tris hydrochloride 
HCl to pH 6.8 
H2O to 500 ml  
2 g SDS 
 
SDS-PAGE running buffer (10-fold)  
 
0.25 M Tris 
2 M Glycin 
1 % SDS  
pH 8.3 
 
Wet transfer buffer  
 
25 mM Tris 
190 mM Glycin  
20 % (v/v) Methanol  
pH 8.0 
Wash buffer (10-fold) pH 7.8  
 
261.4 g tris HCl  
53.99 tris 
876.6 g NaCl 
100 ml tween-20   
H2O to 10000 ml 
 
Blocking solution 
 
5 % milk powder in wash buffer  
 
Laemmli buffer (6-fold)  
 
1.2 g SDS 
0.06 g bromphenol blue 
4.7 ml glycerol 
1.2 ml tris pH 6.8 (0.5 M) 
4.1 ml H2O  
0.939 g DTT 
 
 
 
4.1.4. Kits  
 
InviTrap® Spin Cell RNA Mini Kit    Stratec 
 
 
 
 
 
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
 23 
4.1.5. Cytokine ELISA sets 
 
Human IL-22     R & D Systems, Minneapolis, USA  
Human IL-10     R & D Systems, Minneapolis, USA 
Human VEGF     R & D Systems, Minneapolis, USA 
 
 
4.1.6. Enzymes 
 
Collagenase D     Roche, Mannheim, German 
DNase II      Roche, Mannheim, Germany   
Trypsin (10 x)     PAA, Pasching, Germany 
 
 
4.1.7. Cytokines  
 
Recombinant human IL-22   Peprotech 
Recombinant human IFN-γ   Peprotech 
Recombinant human TNF-α   Peprotech 
 
 
4.1.8. Antibodies 
4.1.8.1. Western blot antibodies 
 
Table 3: Primary antibodies 
Description Isotype Clone  Company 
Mouse IL-22 Rα1 antibody Rat IgG2A 496504 R&D Systems 
β-actin (C4) sc-47778 HRP Mouse IgG1 C4 Santa Cruz 
Phospho-Stat3 (Thyr705) Mouse IgG2b B-7 Santa Cruz 
Stat3 Mouse IgG1 F-2 Santa Cruz 
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Table 4  Secondary antibodies 
Description Isotype Clone  Company 
Goat anti-rabbit IgG HRPsc-
2301 
Goat IgG Polyclonal Santa Cruz 
Goat anti-rat IgG HRP sc-2006 Goat IgG Polyclonal Santa Cruz 
Anti-Mouse IgG, HRP-linked 
antibody 
Horse IgG Polyclonal Cell signaling 
 
 
4.1.8.2. FACS antibodies  
 
Table 5: Directly conjugated FACS antibodies 
Description Isotype Clone  Company 
Annexin V Chicken 
recombinant 
n.a. Immunotools 
Anti-Human IL-17A eFluor® 
450 
Mouse IgG1, κ  eBio64DEC17 eBioscience 
Anti-human PE/Cy7 IL-17A 
antibody 
Mouse IgG1, κ BL168 Biolegend 
Anti-human APC CD3 
antibody 
Mouse IgG2a, κ OKT3 Biolegend 
Anti-human IL-22 PE Mouse IgG1, κ  22URTI eBioscience 
Anti-human APC IFN-γ 
antibody 
Mouse IgG1, κ 4S.B3 Biolegend 
Anti-human PerCP/Cy5.5 
IFN-γ antibody 
Mouse IgG1, κ 4S.B3 Biolegend 
Anti-human FITC CD4 
antibody 
Mouse IgG2b, κ OKT4 Biolegend 
Anti-Human CD8a eFluor® 
450 
Mouse IgG2a OKT8 eBioscience 
    
Mouse IgG1, κ Isotype 
Control PE/Cy7  
Mouse (BALB/c) 
IgG1, κ 
MOPC-21 Biolegend 
Mouse IgG1, κ Isotype 
Control PerCP/Cy5.5  
Mouse (BALB/c) 
IgG1, κ 
MOPC-21 Biolegend 
Mouse IgG1 K Isotype 
Control PE 
Mouse IgG1, 
kappa 
P3.6.2.8.1 eBioscience 
Mouse IgG1 K Isotype 
Control eFluor® 450 
Mouse IgG1, 
kappa 
P3.6.2.8.1 eBioscience 
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4.1.9. Primers for qRT-PCR 
 
Table 6: qRT-PCR primers 
Description Sequence 5´- 3´ 
 
Primer 
efficiency 
Molecular 
Probe # 
CCL20 forward 5´- GCT GCT TTG ATG TCA GTG CT-3´ 
CCL20 backward 5´- GCA GTC AAA GTT GCT TGC TG-3´ 
1,809 39 
CCL22 forward 5´- CCC CCT GAC CCC TCT AAC -3´ 
CCL22 backward 5´- GGA ACA GGA CCC TCT GAC TG-3´ 
1,926 13 
HPRT forward 5´-CGA GCA AGA CGT TCA GTC CT-3´ 
HPRT backward 5´-TGA CCT TGA TTT ATT TTG CAT ACC-3´ 
1,952 73 
IL-22 forward 5´- CAA CAG GCT AAG CAC ATG TCA -3´ 
IL-22 backward 5´- ACT GTG TCC AGC TTT TGC -3´ 
2,042 6 
IL-22-R1 forward 5´-CAC CTC CCA ACT CCC TGA-3´ 
IL-22-R1 backward 5´-CGT GCT CCT GGA TGA AGC-3´ 
2,130 28 
IP10 forward 5´-GAA AGC AGT TAG CAA GGA AAG GT-3´ 
IP10 backward 5´-GAC ATA TAC TCC ATG TAG GGA AGT GA-3´ 
2,104 34 
 
  
4.1.10. Human cell lines 
 
Human colorectal cancer cell lines 
Caco-2 kindly provided by Dr. Andreas Herbst,  
Medizinische Klinik II, Klinikum der Universität München  
Colo205  kindly provided by Universitätsklinikum Hamburg Eppendorf,  
   UCCH Hubertus Wald Tumorzentrum 
DLD-1   kindly provided by Dr. Andreas Herbst, Med. Klinik II Klinikum  
   der Universität München 
HCT116   kindly provided by Dr. Andreas Herbst, Med. Klinik II Klinikum  
   der Universität München 
HT29    kindly provided by Dr. Andreas Herbst, Med. Klinik II Klinikum  
   der Universität München 
SW480   kindly provided by Dr. Andreas Herbst, Med. Klinik II Klinikum  
   der Universität München 
SW620  kindly provided by Prof. Dr. Klaus-Peter Janssen, Department of  
   Surgery, Technische Universität München  
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Other human cell lines  
Karpas 299  kindly provided by Deutsches Krebsforschungszentrum   
   Heidelberg (DKFZ) 
 
 
4.1.11. Equipment 
 
Balance (LP 6209)      Sartorius, Göttingen, Germany 
Cell culture CO2 incubator (BD 6220)   Heraeus, Hanau, Germany 
Cell culture laminar flow     Heraeus, Hanau, Germany 
Centrifuge 5417 R      Eppendorf, Hamburg, Germany 
Centrifuge 5424      Eppendorf, Hamburg, Germany 
FACSCanto II       Becton Dickinson, San Jose,  
       USA 
Gel electrophoresis systems     Bio-rad, Munich, Germany 
LightCycler 2.0 System     Roche, Mannheim, Germany 
Mithras LB940 multilabel plate reader   Berthold, Bad Wildbad, Germany 
Multifuge 3L-R     Heraeus, Hanau, Germany 
Nanodrop ND-1000      NanoDrop, Wilmington, USA 
Neubauer hemocytometer Optik Labor   FrischknechtBalgach, Germany 
Omnifuge 2 ORS      Heraeus, Hanau, Germany 
pH meter       WTW, Weilheim, Germany 
Power Supply 200/2.0     Biorad, Munich, Germany 
Refrigerators (4°C, -20°C, -80°C)    Thermo Scientific, Waltham, USA 
Shaker       NeoLab, Heidelberg, Germany 
Thermocycler T3      Biometra, Göttingen, Germany 
Thermomixer       Eppendorf, Hamburg, Germany 
Vortex VF2       Janke & Kunkel, Staufen,   
       Germany 
 
 
 
 
 
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
 27 
4.1.12. Patient samples 
 
Irreversibly anonymized consecutive tumor samples from patients suffering from cancer 
of the colon or the rectum were collected by Dr. Jens Neumann, Pathologisches Institut, 
LMU, Munich. Analysis of anonymised patient tissue samples was performed as 
approved by the local ethics committee. 
 
Table 7: Tumor and normal tissue samples details  
Patient	  	   Sample	  
number	  	   Histology	  
Age	  at	  
diagnosis	   Gender	   Localization	  
C1	   Adenocarcinoma	   70	   Male	   Coecum	  
C2	   Adenocarcinoma	   70	   Male	  
Colon	  
ascendens	  
1	  
N1/2	   Normal	  tissue	   70	   Male	  
Colon	  
ascendens	  	  
C3	   Adenocarcinoma	   67	   Female	  
Colon	  
ascendens	  
2	  
N3	   Normal	  tissue	   67	   Female	  
Colon	  
ascendens	  
C4	   Adenocarcinoma	   66	   Female	   Rektum	  3	  
N4	   Normal	  tissue	   66	   Female	   Rectum	  
C5	   Adenocarcinoma	   66	   Male	  
Colon	  
ascendens	  
4	  
N5	   Normal	  tissue	   66	   Male	  
Colon	  
ascendens	  
C6	   Adenocarcinoma	   85	   Female	   Rectum	  5	  
N6	   Normal	  tissue	   85	   Female	   Rectum	  
C7	   Adenocarcinoma	   82	   Male	   Rectum	  6	  
N7	   Normal	  tissue	   82	   Male	   Rectum	  
C8	   Adenocarcinoma	   59	   Male	   Sigma	  7	  
N8	   Normal	  tissue	   59	   Male	   Sigma	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Table 8: Tumor and normal tissue sample staging of tumor.  Abbreviations are: T = tumor, N 
= nodes, Ln = lymph nodes, M = metastasis, L = lymphatic vessel invasion, V = vein invasion, Pn 
= perineural invasion, UICC = Union internationale contre le cancer 
Patient	  	   Sample	  
number	  	   Grading	   T	   N	  
Number	  
Ln	   M	   L	   V	   Pn	  
UICC-­‐
Stadium	  
R-­‐
Status	  
C1	   2	   3	   1b	   3/47	  
1b	  
(PER)	   0	   0	   0	   IVB	   Rx	  
C2	   2	   3	   1b	   3/47	  
1b	  
(PER)	   1	   0	   0	   IVB	   Rx	  
1	  
N1/2	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
C3	   3	   4b	   2b	   18/23	  
1b	  
(PER)	   1	   1	   0	   IVB	   Rx	  
2	  
N3	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
C4	   2	   3	   2b	   12/42	   x	   1	   0	   0	   IIIC	   R0	  3	  
N4	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
C5	   2	   3	   1b	   2/24	   x	   1	   2	   3	   III	   R0	  4	  
N5	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
C6	   3	   3	   2a	   4/13	  
1a	  
(HEP)	   1	   0	   1	   IVA	   R0	  
5	  
N6	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
C7	   3	   4b	   0	   0/17	   x	   0	   0	   0	   IIC	   R0	  6	  
N7	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
C8	   3	   4b	   0	   0/32	   x	   0	   0	   0	   IIC	   R0	  7	  
N8	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
 
 
4.1.13. Computer programs 
Adobe Creative Suite      Adobe Systems, San Jose, USA 
BD FACSDiva      BD Biosciences, San Diego, USA 
Endnote X4       Thompson Reuter, Carlsbad, USA 
Flowjo887       Tree Star, Ashland, USA  
GraphPad Prism, Version 5.0b   GraphPad Software, La Jolla, USA 
Microsoft Office          Microsoft, Redmond, USA 
Light Cycler 480 software release           
1.5.0 SP4      
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4.2.  Methods 
4.2.1.  Molecular biology 
4.2.1.1. Isolation of cytoplasmatic RNA 
 
To isolate RNA from human colon cancer cell lines the InviTrap® Spin Cell RNA Mini Kit 
(Stratec) was used. Purification was done according to the protocol provided by the 
manufacturer.  
 
 
4.2.1.2. Reverse transcription 
 
Complete RNA was reversely transcribed in first strand copy-DNA (cDNA) using the 
RevertAid First Strand cDNA Synthesis Kit. 1 - 2 µg of total RNA was used. For low 
concentrated samples a maximum of 11 µl of RNA was used. The RNA was mixed with 
Oligo-(dT)18 primer, 5 x Reaction buffer, RiboLock RNase Inhibitor, dNTP Mix and 
RevertAid M-Mul reverse transcriptase. cDNA was either directly used or stored at  
-20°C. 
 
 
4.2.1.3. Real time quantitative reverse transcription PCR (qRT-PCR) 
 
To quantify mRNA levels qRT-PCR was used. 2 µl of cDNA was mixed with 5 µl of 
molecular probe master mix, 0.4 µl forward primer, 0.4 µl backward primer, 3 µl H2O and 
0.2 µl molecular probe. 
 
Analysis was performed using a LightCycler 2.0 System (Roche) and quantification 
using Light Cycler 480 software release 1.5.0 SP4. HPRT was used as reference gene. 
For stimulations of colorectal cancer cells with cytokines, expression was normalized to 
unstimulated controls (set to 1). 
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4.2.2.  Cell culture methods 
4.2.2.1. General conditions 
 
Cell culture was carried out under a laminar flow hood to ensure sterile conditions. The 
cells were grown in commercially available disposable tissue culture flasks and dishes, 
and incubated at 37ºC, 5% CO2 - air mixture and 95% atmospheric humidity.  
Cell numbers and viability were tested by trypan blue staining. Cells were counted using 
a Neubauer hemocytometer. 
 
 
4.2.2.2. Culturing medium for human cell lines 
 
Table 9: Culturing medium for human cell lines and primary cells 
Cell line(s) Medium 
Caco-2 
HCT116 
DLD-1 
SW480 
SW620 
 
DMEM supplemented with 10% heat inactivated fetal calf serum 
(FCS), 2 mM L-glutamine, penicillin (100 U/l), streptomycin (0.1 
mg/ml) 
 
 
Colo205 
Karpas299 
RPMI medium supplemented with 10% heat-inactivated FCS, 2 
mM L-glutamine, penicillin (100 U/l), streptomycin (0.1 mg/ml) 
 
HT29  McCoy’s 5A medium supplemented with 10% heat inactivated 
FCS, 2 mM L-glutamine, penicillin (100 U/l), streptomycin (0.1 
mg/ml) 
 
 
4.2.2.3. Cell stimulations using recombinant cytokines 
Colorectal cancer cell lines were stimulated with IL-22 (50 ng/ml), IFN-γ (10 ng/ml) and 
TNF-α (20 ng/ml) alone or in combination. For stimulation, cells were plated onto 6- or 
24-well plates and allowed to adhere overnight. Medium was removed and cells were 
washed once with PBS. For STAT3 and pSTAT3 stimulation cells were starved 4 h in 
Opti-MEM prior to stimulation with recombinant IL-22. For proliferation assays, a 
Neubauer chamber was used for cell quantification. 
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4.2.2.4. Preparation of whole protein lysates from colorectal cancer cell 
lines 
 
Cells grown in suspension were collected and adherent cells were detached by 
trypsinization. Cells were washed once with PBS and pellets were resuspended in 1 x 
lysis buffer supplemented with protease inhibitor cocktail. Cells were kept 30 - 45 min on 
ice and vortexed shortly every 10 min. Cell debris was removed by centrifugation for 15 
min at maximum rpm at 4 °C. Cell lysates were stored at -20 °C. 
 
 
4.2.3.  Immunological methods 
4.2.3.1. Bradford assay  
 
Total protein concentration of lysates from colorectal cancer cells was assessed using 
the Bradford method (Bradford, 1976).  
 
 
4.2.3.2. SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
To separate proteins according to their molecular mass, SDS-PAGE was used. Protein 
samples were boiled for 5 min at 95 ºC in Laemmli buffer (Laemmli, 1970) under 
reducing conditions (including β-mercaptoethanol). Proteins were separated at a 
constant voltage of 100 V. 
 
 
4.2.3.3. Western blot 
 
After SDS Page, proteins were transferred onto a PVDF membrane at 360 Ampere for 
60 min. Unspecific binding was blocked with 5% milk powder in TBST for 60 min at room 
temperature (RT). RT is defined as the temperature that is currently in the laboratory. 
Membranes were incubated with primary antibody overnight at 4 °C. Secondary antibody 
was incubated 60 - 120 min at RT. Afterwards the membrane was washed 3 x and 
Western blotting substrate was applied to the membrane. Chemo luminescence was 
detected using a CCD camera system (ImageQuant LAS 4000 mini). 
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
 32 
4.2.3.4. Enzyme-linked immunosorbent assay (ELISA) 
 
Cytokine concentrations of culture supernatant were determined by using sandwich 
ELISA, according to the protocol of the manufacturer.  
 
 
4.2.3.5. Flow cytometry 
 
All measurements were performed on an analytical FACS Canto II three laser system. 
 
 
4.2.3.5.1. Analysis of surface molecule expression 
 
Expression of surface molecules was assessed by adding fluorochrome-conjugated 
monoclonal antibodies.  
 
 
4.2.3.5.2. Intracellular cytokine staining 
 
Cells were stimulated with PMA (50 ng/ml) and ionomycin (1µg/ml) in the presence of 
Golgistop (brefeldin A, 4 µg/ml) for 4 - 5 h at 37 °C of intracellular cytokine expression 
analysis. Afterwards cells were washed 2 x with PBS and surface antigens were stained. 
Cells were then fixed using IC Fixation (eBioscience) for 20 min at RT. Cells were 
washed 1 x with PBS and left over night in PBS at 4 °C. 
After washing cells twice with 1 x permeabilisation buffer (eBioscience), cells were 
stained in 100 µl 1 x permeabilisation buffer supplemented with fluorochcrome-
conjugated monoclonal antibodies against the cytokines of interest for 30 min at 4 °C. 
Afterwards cells were washed 1 x with 1 x permeabilisation buffer, 1 x with PBS.  
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4.2.3.5.3. Apoptosis assay: Annexin V and PI staining 
 
Apoptosis assay was performed using Annexin V and propidium iodide (PI) staining. 
Cells were harvested and transferred to FACS tubes and washed 1 x with PBS. 
Afterwards 200 µl 1 x Annexin V buffer was added per tube together with Annexin V 
APC antibody. Shortly before FACS analysis, PI was added. 
 
 
4.2.3.5.4. Preparation and staining of colorectal cancer tissue 
 
Samples from colorectal cancer patients were collected and stored at 4 °C in complete 
RPMI until digestion of the sample with 1 mg/ml collagenase and 0.05 mg/ml DNAse I at 
37 °C for 30 min under mild shaking. Tissues were then sequentially dissociated by 
mashing through 100 µm and 40 µm cell strainers to generate single cell suspension. 
Cells were stimulated as described above. Cells were washed 2 x with PBS and fixable 
live dead staining was performed in 1 ml PBS for 30 min at 4°C. Cells were fixed and 
stored overnight at 4 °C after surface staining.  
 
Intracellular staining was performed using IL-22, IL-17A and IFN-γ specific antibodies as 
well as appropriate isotype controls. 
 
 
4.3. Statistical analysis 
 
Columns and error bars indicate means and standard errors of the mean (SEM). 
Differences in experimental data sets were analyzed using unpaired (patient samples) or 
paired (cell culture experiments) two-sided Student’s t-test. p < 0.050 are considered as 
statistically significant. Number of independent experiments is stated for each figure. 
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5.  Results 
5.1.  Cellular sources of IL-22 in human tissue 
5.1.1.  Frequencies of IL-22 producing T cells in human PBMC 
 
To evaluate Th-22 cell function in experiments, the frequency of Th-22 cells was evaluated 
in PBMC of 8 healthy individuals. Th-22 cells are defined as CD4+ T cells that produce IL-
22 in the absence of IL-17 and IFN-γ. The gating strategy is shown in figure 4. We defined 
Th-22 cells as CD3+ CD4+ CD8- IL-17- IL-22+ and IFN-γ-. Th-17 cells were defined as CD3+ 
CD4+ CD8- IL-17+ and IFN-γ-, and Th1 cells as CD3+ CD4+ CD8- and IFN-γ+. Th-22 and 
Th-17 cells were found at low frequencies, in contrast to Th-1 cells which were the most 
abundant Th-subpopulation. The frequency range of Th-22 cells was 0.3 – 0.7 %, the 
range of Th-17 was 0.3 – 0.8 % and the range of Th-1 cells was 3.7 – 10.1 % (see figure 
5).  
 
 
Figure 4: Gating strategy example of one healthy donor.  Samples from a total of 8 healthy 
donors were purified by Biocoll density gradient centrifugation and restimulated with PMA and 
ionomycin in the presence of brefeldin A. PBMC were stained for surface CD3, CD4 and CD8 as 
well as for intracellular IL-22, IL-17A and IFN-γ. Results are shown for one representative donor. 
CD3+  CD4+ CD8+ T cells were analyzed for their IL-22 and IL-17A production. Numbers indicate 
relative percentages per quadrant.  
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Figure 5: Frequencies of IL-22-producing T cells in PBMC of healthy donors. Samples from a 
total of 8 healthy donors were purified by Biocoll density gradient centrifugation and restimulated 
with PMA and Ionomycin in the presence of brefeldin A. PBMC were stained for CD3, CD4 and CD8 
surface staining as well as intracellular staining for IL-22, IL-17A and IFN-γ. Frequencies of Th-22 
(CD3+ CD4+ CD8- IL-22+ IL-17A- IFN-γ-), Th-17 (CD3+ CD4+ CD8- IL-17+IFN-γ-), and Th-1 (CD3+ 
CD4+ CD8- IFN-γ+) cells within the CD3+ cell population. Mean with SEM is indicated. 
 
 
While CD4+ T cells are the main producers of IL-22, low frequencies of IL-22+ CD8+ T cells 
were also detected (see figure 6).  
 
A  B  
 
 
 
  
Figure 6: CD8+ IL-22 producing T cells in PBMC from healthy donors. PBMC of a total of 8 
healthy donors were purified by Biocoll density gradient centrifugation and restimulated with PMA 
and Ionomycin in the presence of brefeldin A. CD3, CD4 and CD8 surface staining as well as 
intracellular staining for IL-22, IL-17A and IFN-γ was performed. (A) One representative donor is 
shown as FACS blot gated from CD3+ CD8+ T cells. (B) Frequencies of IL-22+ cells within CD3+ 
CD8+ T cells of 8 donors. Mean with SEM is indicated. 
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5.1.2. T-helper cell subpopulations producing IL-22 are found in the tumor tissue of 
colorectal cancer patients 
 
To further dissect the role of IL-22 in tumor biology, we applied the above described 
technique to analyze IL-22-producing cells in primary colorectal cancer tissue. For each 
patient a tissue sample from the tumor and a sample from neighboring tissue 
macroscopically not affected by the tumor (herein referred to as ‘normal tissue’) were 
collected.   
 
Samples from patients with colorectal cancer were analyzed for CD3, CD4 and CD8 
surface expression and IL-22, IL-17 and IFN-γ intracellular cytokine staining.  
 
Figure 7 shows the numbers of Th-1, Th-17 and Th-22 as proportions of CD3+ T cells 
Numbers of Th-17 and Th-22 were low compared to Th-1 cells.  For Th-17 and Th-1 cells 
there is a trend towards higher numbers in tumor tissue. However, the frequencies of Th-1, 
Th-17 and Th-22 cells are not significantly different in tumor compared to normal tissue. 
 
   
 
Figure 7: Frequencies of Th-22, Th-17 and Th-1 in samples from colorectal cancer patients. 
CD3, CD4 and CD8 surface staining as well as intracellular staining for IL-22, IL-17A and IFN-γ 
were performed. Frequencies of Th-22 (CD3+ CD4+ CD8- IL-22+ IL-17A- IFN-γ-), Th-17 (CD3+ 
CD4+ CD8- IL-17+IFN-γ-), and Th-1 (CD3+ CD4+ CD8- IFN-γ+) cells within the CD3+ CD4+ CD8- cell 
population of tumor and normal tissue from 7 patients are shown, for one patient with dual 
carcinoma two specimens were taken. Mean with SEM is indicated. 
 
A population of IL-22+ T cells that was IFN-γ+ (CD3+CD8-CD4+IL-17-IL-22+) T cells was 
found in higher numbers in normal tissues compared to tumor tissue (p=0.046) (figure 8A).  
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A  B  
 
 
 
Figure 8: Frequencies of tumor infiltrating lymphocytes. Lymphocytes were isolated from 
colorectal cancer biopsies and restimulated with PMA and Ionomycin in the presence of brefeldin A. 
Afterwards CD3, CD4 and CD8 surface staining as well as intracellular staining for IL-22, IL-17A 
and IFN-γ was performed. (A) Frequencies of CD3+CD8-CD4+IL-17- IL-22+ within CD4+ T cells. (B) 
CD8+ IL-22 producing T cells are found in normal and colorectal cancer tissue. Results of normal 
and cancer tissue from 7 patients are shown, for one patient with dual carcinoma two specimens 
were taken. Mean with SEM is indicated.  
 
 
Using flow cytometry, we found a proportion of the CD8+ T cells to stain positive for IL-22. 
Equal amounts of IL-22 producing CD8+ T cells were found in normal and tumor tissue 
(p=0.252) (figure 8B).  
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5.2. Effect of IL-22 on human colorectal cancer cell lines 
 
To understand the effect of IL-22 production at the tumor site, we next performed in vitro 
assays using a panel of human colorectal cancer cell lines (n = 6).  
 
 
5.2.1. Colorectal cancer cell lines do not produce IL-22 
 
To test if colorectal cancer cell lines have the ability to produce IL-22, we tested Colo205, 
CaCo2, DLD-1, HCT116, HT29 and SW480 for IL-22 secretion by ELISA and IL-22 
expression by qRT-PCR. The tested cell lines do not secrete IL-22 and no significant 
mRNA levels were found for the IL-22 transcript, indicating that these colorectal cancer cell 
lines do not produce IL-22 (figure 9) 
 
 
A  B  
  
Figure 9: Colorectal cancer cell lines do not produce IL-22. (A) Analysis of IL-22 mRNA in 
colorectal cancer cell lines by qRT-PCR. For qRT-PCR data relative expression of IL-22 to 
hypoxanthin-phosphorybosyltransferase (HPRT) for each cell line was calculated by the Light 
Cycler relative quantification software. The human lymphoma cell line Karpas 299 served as 
positive control. (B) Supernatants of colorectal cancer cell lines were tested for IL-22 content by 
ELISA. The cell line Karpas 299 served as positive control. The error bars represent standard error 
of the mean of duplicates. Results are representative for at least two independent experiments.  
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5.2.2. Colorectal cancer cells express IL-22-R1 
 
To further dissect the potential role of IL-22 in colorectal cancer, we next studied 
expression of IL-22-R1 on colorectal cancer cell lines. IL-22-R1 expression was assessed 
by Western blot analysis and qRT-PCR. IL-22-R1 was found in all cell lines analyzed on 
mRNA and on protein level (figure 10).  
 
A B  
 
   
 
 
Figure 10: Colorectal cancer cell lines express IL-22-R1 on mRNA and protein level. (A) 
Analysis of IL-22-R1 mRNA in colorectal cancer cell lines by qRT-PCR. For qRT-PCR data relative 
expression of IL-22-R1 to HPRT for each cell line was calculated by the Light Cycler relative 
quantification software. (B) 40 µg protein of whole cell lysate was loaded per lane. IL-22-R1 
expression was detected by Western blot. β-actin served as loading control. One representative of 
at least two is shown.  
 
 
5.2.3. IL-22 signaling pathway is functional in colorectal cancer cells 
 
In cancer cells, STAT3 is the major signal transducing molecule upon IL-22 stimulation. 
To test ability of the six colorectal cancer cells lines to respond to IL-22 stimulation, cells 
were treated with 100 ng/ml IL-22 for 10, 30 and 60 min and analyzed for STAT3 
phosphorylation by Western blot. 
 
All tested colorectal cancer cell lines (Colo205, CaCo2, DLD-1, HCT116, HT29 and 
SW480) responded to IL-22 stimulation by STAT3 phosphorylation. Phosphorylation of 
STAT3 is shown exemplarily in figure 11 for the cell lines HT29 and Colo205.  
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Figure 11: STAT3 is phosphorylated in colorectal cancer cell lines upon IL-22 stimulation. 
Colorectal cancer cell lines were either left unstimulated (unst.) or stimulated with IL-22 (100 ng/ml) 
for the indicated time periods. Phospho-STAT3 (pSTAT3) was evaluated by Western blot analysis. 
STAT3 and β-actin served as loading controls. Colo205 (A) and HT29 (B) showed STAT3 
phoshorylation upon IL-22 stimulation. One representative of at least two independently performed 
experiments is shown.  
 
 
5.2.4. IL-22 stimulation induces release of IL-10 and VEGF from Colo205 cells 
 
To further dissect the downstream effects of IL-22 stimulation, we analyzed the secretion 
of IL-10 and VEGF, which are both induced by pSTAT3 activation. Upon IL-22 stimulation, 
IL-10 secretion was induced (figure 12A) and VEGF secretion was enhanced in a time 
dependent manner (figure 12B).  
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Figure 12: IL-22 induces IL-10 secretion from Colo205 cells. Colo205 cells were seeded in 96 
well plates and stimulated with 50, 100 or 200 ng/ml IL-22. Supernatants were collected at 6, 24 
and 48 h and the (A) IL-10 content and (B) VEGF concentration was measured by ELISA. One 
representative experiment of three independent experiments is shown. Error bars represent SEM of 
duplicates. 
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5.2.5. IL-22 induces proliferation of Colo205 cells 
 
Another consequence of STAT3 phosphorylation in cancer cells is cell proliferation. To 
analyze if IL-22 stimulation would induce proliferation of colorectal cancer cells, we 
stimulated Colo205 cells with different concentrations of IL-22 (see figure 13). Shown are 
fold change normalized to unstimulated controls after 48 hours. IL-22 stimulation dose-
dependently induced proliferation of Colo205 cells (figure 15, p = 0.023) for the 100 ng/ml 
condition versus unstimulated).  
 
 
   
Figure 13: Colo205 cells proliferate upon IL-22 stimulation in a concentration dependent 
manner. Proliferation is measured as cell number by Neubauer chamber counting in the presence 
or absence of IL-22 (50 ng/ml or 100 ng/ml) for the cell line Colo205. Number of cells was 
normalized to unstimulated controls. The results of one representative experiment of three 
independent experiments are shown. Error bars represent Mean with SEM of triplicates. Paired t-
test, p<0.05 represents significant difference. 
 
 
  
5.3. Effect of IL-22 on IFN-γ-induced CCL22 production of tumor cells 
5.3.1. IL-22 inhibits IFN-γ-induced CCL22 secretion in HT29 cells 
 
Because IL-22 may interact with the downstream effects of IFN-γ, we sought to further 
investigate the effect on other IFN-γ-mediated effects such as chemokine secretion (Berin 
et al, 2001; Kaplan et al, 1987; Pennino et al, 2013). The colorectal cancer cell line HT29 
produces CCL22 after IFN-γ stimulation (Berin et al, 2001).  
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HT29 cells were either stimulated with IFN-γ, IL-22 or the combination of both. CCL22 
induction was analyzed by qRT-PCR and ELISA. IFN-γ stimulation induced CCL22 (see 
figure 14A). Addition of IL-22 significantly reduced IFN-γ-induced CCL22 secretion (p = 
0.002). However, for IP10 and CCL20 no significances were calculated since the sample 
number was too low (figure 14B und 14C). 
A  
 
 
B C 
  
Figure 14: IL-22 downregulates IFN-γ-induced CCL22 in HT29 cells. HT29 cells were treated 
with IFN-γ (10 ng/ml) or IL-22 (50 ng/ml) for two days in Opti-MEM. Cells were harvested and RNA 
was extracted. mRNA expression was determined by qRT-PCR for CCL22, IP10 and CCL20. For 
qRT-PCR data relative expression of IL-22-R1 to HPRT for each cell line was calculated by the 
Light Cycler relative quantification software and the mean of untreated control HT29 cells was set to 
1. (A) Relative expression of CCL22 in HT29 cells is shown. Error bars represent mean with SEM of 
seven independent experiments. (B) Relative expression of IP10 in HT29 cells is shown. Error bars 
represent mean with SEM of two independent experiments. (C) Relative expression of CCL20 
expression in HT29 cells. Error bars represent mean with SEM of two independent experiments. 
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To exclude that the IL-22 effect on IFN-γ –induced CCL22 production was due to 
apoptosis induction, Annexin V and PI staining on HT29 cells after stimulation was 
performed. The combination of IL-22 and IFN-γ did not significantly increase the number of 
Annexin V and PI positive cells (p=0.265) (figure 15). 
 
 
 
Figure 15: Apoptosis and Death of HT29 cells stimulated 2 days in Opti-MEM supplemented 
with IFN-γ, IL-22 or both. Data are representative for at least two independent experiments. Error 
bars represent mean with SEM of triplicates. Paired t-test, p<0.05 represents significant difference. 
 
 
5.3.1.1. IFN-γ upregulates IL-22-R1 on colorectal cancer cells 
 
Because IFN-γ has been described to upregulate IL-22-R1 on keratinocytes (Kunz et al, 
2006), we next asked whether this effect could also be observed in colorectal cancer cell 
lines. HT29 and Colo205 cells were stimulated with IFN-γ or IL-22 and IL-22-R1 
expression was analyzed by RT-PCR. IL-22 did not significantly enhance IL-22-R1 
expression in HT29 (p=0.067) (figure 16A) and in Colo205 (0.139) cells (figure 16B). IFN-γ 
enhanced IL-22-R1 expression significantly in HT29 cells (p=0.001). However the 
induction of IL-22-R1 was not significant in Colo205 cells (p=0.091).  
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Figure 16: IFN-γ upregulates IL-22-R1 expression in HT29 and Colo205 cells. HT29 (A) and 
Colo205 (B) cells were treated with IFN-γ (10 ng/ml) or IL-22 (50 ng/ml) for two days. Cells were 
harvested and cDNA was prepared. mRNA expression was determined by qRT-PCR for IL-22-R1. 
The mRNA expression of each condition was normalized to expression of HPRT mRNA and the 
mean of untreated control HT29 and Colo205 cells was set to 1.0, respectively. Error bars represent 
mean with SEM of four (HT29 cells) and three (Colo205) independent experiments. Paired t-test, 
p<0.05 represents significant difference. 
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5.3.1.2. IL-22 and TNF-α synergistically induce CCL22 in HT29 cells 
 
HT29 and Colo205 cells were stimulated with IL-22, TNF-α or the combination of both. 
TNF-α induced CCL22 expression in HT29 cells. Addition of IL-22 to TNF-α significantly 
increased CCL22 expression in HT29 cells (p = 0.021) (figure 17).  
 
 
Figure 17: IL-22 synergizes with TNF-α- to induce CCL22 expression in HT29 cells. HT29 cells 
were treated with TNF-α (20 ng/ml) or IL-22 (50ng/ml) for two days in Opti-MEM. Cells were 
harvested and mRNA and subsequent cDNA was prepared. mRNA expression was determined by 
real-time PCR for CCL22. The mRNA expression of each condition was normalized to expression of 
HPRT mRNA and the mean of untreated control HT29 cells was set to one. CCL22 expression in 
HT29 cells is shown. Error bars represent mean with SEM of five independent experiments. 
 
 
 
5.3.1.3. TNF-α  induced upregulation of IL-22-R1 expression in HT29 cells 
 
To further understand the interaction of IL-22 and TNF-α on colorectal cancer cells, we 
next investigated the impact of TNF-α on IL-22-R1 expression. IL-22 did not significantly 
upregulate IL-22-R1. TNF-α and the combination with IL-22 both upregulated IL-22-R1 
expression in HT29 cells significantly, p=0.018 and p=0.036, respectively (see figure 18). 
The combination of TNF-α with IL-22 showed a trend towards further enhancement of IL-
22-R1 expression. 
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Figure 18: TNF-α upregulates IL-22-R1 in HT29 cells. HT29 cells were treated with IL-22 (50 
ng/ml) or TNF-α (20ng/ml) alone or in combination for two days in Opti-MEM. Cells were harvested 
and cDNA was prepared. mRNA expression was determined by real-time PCR for IL-22-R1. The 
mRNA expression of each condition was normalized to expression of HPRT mRNA and the mean of 
untreated control HT29 and Colo205 cells was set to one. Error bars represent Mean ± SEM of four 
independent experiments. 
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6.  Discussion 
 
The present work shows that human PBMC from healthy donors as well as colorectal 
cancer tissue contain subclasses of IL-22 producing T cells, including Th-1, Th-17 and 
Th-22 cells as detected by flow cytometry. Low frequencies of CD8+ IL-22 secreting T 
cells were also detected.  
 
Colorectal cancer cell lines did express IL-22-R1 but not IL-22. IL-22 stimulation induced 
STAT3 phosphorylation in all tested cell lines. In Colo205 cells IL-22 led to VEGF and IL-
10 release as well as cell proliferation. We also showed that IL-22 suppresses IFN-γ-
induced CCL22 protein expression in HT29 cells. In addition, IL-22 enhanced TNF-α-
induced expression of CCL22 in the same cell line. Both IFN-γ and TNF-α upregulated 
expression of IL-22-R1. 
 
 
6.1.  IL-22 expression in human PBMC from healthy donors 
 
Our study shows that IL-22 producing T cells can be detected in PBMC. Different Th cell 
subtypes are present within circulating healthy PBMC (Lu et al, 2015; Luan et al, 2015; 
Oliveira et al, 2015).   
 
In this thesis, it was shown that Th-1, Th-17 and Th-22 are present in the peripheral 
blood of healthy donors, consistent with the literature. The focus of the thesis was Th-22 
cells that represent a novel T cell subpopulation. The frequency of Th-22 cells was low. 
Studies by other groups have identified Th-22 cells as a very rare population within 
PBMC from healthy human donors (Liu et al, 2012; Zhang et al, 2012a). One study 
detected a mean of 0.8 % circulating Th-22 cells with a range of 0.3 % to 2.1% for Th-17 
cells a mean of 1.9 % was found (range, 0.4 % to 4.3 %) (Lu et al, 2015). Another study 
described low frequencies with up to approximately 0.1 % CD3+ CD4+ IL-22+ cells 
(Oliveira et al, 2015). An additional study showed for Th-22 cells a median of 0.2 % and 
a range of 0.5 %, for Th-17 cells a median of 0.4 % and a range of 1.5 % and for Th-1 
cells a median of 1.4 % and a range of 15.5 % (Luan et al, 2015). The levels we found 
for Th-22 cells were 0.3 to 0.7 % and 0.3 to 0.8 % for Th-17 cells. For Th-1 cells we 
found levels between 3.7 % and 10.1 %.  
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Th frequencies of Th-22 cells detected in the present thesis are compatible with the low 
frequencies described in literature. Minor differences may result from different cohorts of 
donors as well as from methodological differences. Th-22 cells are found in low 
frequencies in peripheral blood, however they are abundant in tissue. One explanation 
could be the expression of their characteristic chemokine receptors CCR4 and CCR10. 
Chemokines binding these receptors are for instance strongly expressed in the skin 
(Eyerich & Eyerich, 2015). 
 
IL-22 does not act on immune cells but on cells of epithelial origin and therefore 
represents novel kind of immune modulator within the IL-10 family of cytokines (Wolk et 
al, 2010). The main functions of IL-22, in healthy individuals, are increase of innate 
immunity, protection of tissue from damage and enhancement of tissue regeneration.   
 
Particular Th-22 cells have been described to protect epithelial barriers in organs and 
also modulate injured and inflamed tissue (Eyerich & Eyerich, 2015). IL-22 also plays a 
role in the defense against bacterial infections (Siegemund et al, 2009) inducing, for 
instance, antimicrobial molecules (Siegemund et al, 2009; Wolk et al, 2004). 
 
 
6.2. Expression of IL-22 in colorectal cancer tissue 
 
A Th-22 staining protocol was established and applied to tumor samples from colorectal 
cancer patients. The presence of IL-22 and/or of Th-22 cells has previously been 
demonstrated within tumor tissues from patients with colorectal, gastric, hepatocellular, 
small-and large-cell lung carcinoma (Jiang et al, 2013; Kobold et al, 2013; Liu et al, 
2012; Qin et al, 2014). 
 
We detected IL-22 producing Th-1, Th-17 and Th-22 within tumor samples of colorectal 
cancer patients. These findings are in line with published data as all three T cell types 
have been described in solid tumors.  
 
CD4+ T cells were shown to exert a role in both the induction and the effector phases of 
the antitumor response (Protti et al, 2014). It has been described that activated CD4+ T 
cells modulate antitumor immune response. Th-1 cells support cytotoxic T cells and 
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secrete cytokines such as IL-2 or IFN-γ and that promote an antitumor response and 
tissue destruction (Disis, 2010; Pernot et al, 2014).  
 
Th-17 cells are known to be present in the tumor environment of colorectal cancer 
patients. Tumor-infiltrating IL-17 producing CD4+ T cells and macrophages have been 
associated with poor prognosis for colorectal cancer patients (Fridman et al, 2011; 
Fridman et al, 2012; Liu et al, 2011a).  
 
Th-22 cells were the focus of this thesis; their involvement in tumor development and 
role in sustaining established tumors was investigated. We detected low frequencies of 
Th-22 in both tumor tissue and non-affected tissue. However, it has been shown that  
Th-22 cell accumulation may be connected to colorectal cancer development, according 
to published evidence. The authors found increased levels of Th-22 in tumor tissue 
compared to peritumoral tissue (Huang et al, 2015). In this thesis up to 0.9 % of Th-22 
cells as subset of CD4+ T cells were found whereas Huang et al., found up to 1.5 %  
Th-22 cells. The cited publication analyzed a cohort of 18 patients for their Th-22 content 
via FACS as opposed to the seven patients analyzed here. Thus, discrepancies may be 
explained by the low power of either study. A larger cohort might be more suitable for 
comparison of Th-22 in tumor tissue and peritumoral tissue. Peritumoral tissue was used 
in this thesis as control. However, while the cancer cells do not directly affect this tissue, 
it is extracted from the same patient suffering from cancer. The T cell repertoire might 
also be affected by changes resulting either from neighboring cancer cells or by the 
factors leading to cancer development in the first place. Therefore, the peritumoral tissue 
may not be strictly considered a healthy tissue and may not have identical 
characteristics to tissue from a true healthy individual. 
 
Circulating Th-22 are increased in patients with gastric cancer compared to healthy 
donors and are associated with tumor progression (Liu et al, 2012). Another study 
demonstrated increased intratumoral CD4+IL-22+ T cells. The authors correlated Th-22 
to tumor progression and lower patient survival (Zhuang et al, 2012). Circulating Th-22 
cells are also associated with hepatocellular carcinoma development and disease 
progression (Qin et al, 2014). For pancreatic cancer patients, intratumoral IL-22 levels 
and frequencies of CD4+ IL-22 producing cells are as well linked to disease progression 
(Xu et al, 2014).  
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In summary, available data suggests a disease-promoting role of Th-22 in several 
cancer entities. 
 
In contrast, the function of IL-22 may vary according to the stage of the disease where 
IL-22 is expressed. For example, transgenic mice that are characterized by constant 
overproduction of IL-22 in the liver do not spontaneously develop liver tumors (Park et al, 
2011). However, IL-22 may support the progression of already developed tumors, as IL-
22 induces proliferation in a number of tumor cells from various origins (Kobold et al, 
2013).  
 
 
6.3.  Expression of IL-22-R1 and activation of STAT3 
 
To address the question of the effect of IL-22 on colorectal cancer, colorectal cancer cell 
lines were used as an in vitro model.  
 
To verify that colorectal cancer cells themselves do not produce IL-22, six cell lines were 
tested for their IL-22 expression. It is widely accepted that IL-22 is not produced by 
epithelial cells (Wolk et al, 2010). Consistent with this statement, we found no IL-22 
expression on protein level in Colo205, HT29, SW480, DLD-1, HCT-116 and Caco-2 
cells. The findings of this thesis strengthen the hypothesis that IL-22 found in tumor 
tissues is expressed by infiltrating immune cells and not by the tumor cells.  
 
To test the responsiveness of these cell lines, IL-22-R1 receptor expression was 
analyzed. The IL-10-R2 chain of the functional IL-22 receptor complex is ubiquitously 
expressed and is not limiting in defining IL-22-responsive cells (Wolk et al, 2004). Thus, 
cellular responsiveness to IL-22 is determined by the expression of IL-22-R1. All tested 
colorectal cancer cell lines did express IL-22-R1 on protein level. The lymphoma cell 
lines Karpas299 served as positive control as this cell lines has been described to 
express IL-22-R1 (Bard et al, 2008). 
 
The findings of this thesis corroborate previously published findings on colorectal cancer 
cell lines and IL-22-R1 expression (Brand et al, 2006; Di Lullo et al, 2015; Nagalakshmi 
et al, 2004; Ziesche et al, 2007). However, it cannot be concluded that any cancer cell 
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from any origin necessarily expresses IL-22-R1: one study showed that not all tested 
multiple myeloma cell lines did express IL-22-R1. They found IL-22-R1 mRNA in 
approximately one third of the tested cell lines (Di Lullo et al, 2015).  
 
All tested colorectal cancer cell lines showed induction of STAT3 phosphorylation upon 
IL-22 stimulation, as previously published (Brand et al, 2006; Cella et al, 2009; De 
Simone et al, 2014; Nagalakshmi et al, 2004). However, IL-22 can also activate other 
STAT members namely 1 and 5. For all three STATs the major MAPK pathway is 
activated, leading to phosphorylation of ERK1/2, JNK, and p38 kinase after interaction 
with the IL-22-R1/IL-10-R2 receptor complex (Lejeune et al, 2002). In cancer cells, most 
of the downstream effects of IL-22 are thought to be mediated by activation of STAT3 
(Boniface et al, 2005; Nagalakshmi et al, 2004; Xie et al, 2000). STAT3 activation has 
been shown in multiple carcinoma cell lines other than colorectal cancer, such as: in 
human lung carcinoma cell lines (Kobold et al, 2013), gastric carcinoma cell lines (Fukui 
et al, 2014), skin basal-cell carcinoma and squamous-cell carcinoma cell lines 
(Nardinocchi et al, 2015). Since we focused on STAT3 activation for these reasons, we 
cannot rule out a contribution to IL-22 signaling by other downstream effector molecules. 
 
 
6.3.1. IL-22 induces VEGF, IL-10 and proliferation in Colo205 cells 
 
We could show that Colo205 secrete IL-10 upon IL-22 stimulation as previously 
published (Nagalakshmi et al, 2004). Production of IL-10 by Colo205 cells could be a 
mechanism by which tumor cells suppress inflammatory immune responses, since IL-10 
is a crucial anti-inflammatory cytokine (Fiorentino et al, 1991). 
 
On the other hand, we showed that Colo205 cells increased VEGF production upon IL-
22 stimulation, as previously demonstrated in HPAFII human pancreatic cancer cells 
(Curd et al, 2012). A finding which is further corroborated by IL-22+ tumor-infiltrating 
lymphocytes of colorectal cancer patients increasing VEGF expression in mice with 
colorectal cancer xenografts (Jiang et al, 2013).   
 
VEGF directly acts on endothelial cells and is the major angiogenic growth factor for 
cancers and may thus represent a mechanism by which IL-22 could help colorectal 
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cancer progression (Carmeliet & Jain, 2000; Pepper et al, 1992).  
However, none of the other tested colorectal cancer cell lines did produce IL-10 or VEGF 
after IL-22 stimulation, which may indicate a cell line specific over a disease specific 
effect of IL-22.  
 
A number of studies demonstrated proliferation of tumor cells in response to IL-22 
(Brand et al, 2006; Di Lullo et al, 2015; Kobold et al, 2013; Nardinocchi et al, 2015) 
which is further supported by our results of increased proliferation of Colo205 cells upon 
IL-22 stimulation. Supernatants derived from NK-22, which produce IL-22, stimulate 
Colo205 cells to proliferate, which is in line with our data (Cella et al, 2009).  
 
In summary, these findings support the idea that IL-22 may contribute to enhanced 
tumor growth, progression and angiogenesis by cytokine, growth factor and proliferation 
induction.  
 
 
6.4. Crosstalk of IL-22 pathway with signaling of IFN-γ and TNF-α 
 
Multiple cytokines are involved in tumor formation and growth. However, their pro- or 
antitumor role depend on the balance of the different cytokines as well as on the stage of 
the cancer (Landskron et al, 2014). IL-22 can act pro- and anti-inflammatory on tissue 
homeostasis. On the one hand, IL-22 promotes epithelial cell regeneration and protects 
tissues from damage while playing a crucial inflammatory role in a pathological context 
(Nikoopour et al, 2015). The reasons for the dual role of IL-22 in intestinal homeostasis 
are not elucidated but might be related to microbial stimulation and that maintained 
production in response to chronic bacterial stimulation eventually promotes disease 
(Kirchberger et al, 2013). These paradox functions may be explained by the presence or 
absence of other cytokines. 
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6.4.1. IL-22 inhibits IFN-γ-induced CCL22 secretion in HT29 cells  
 
IFN-γ is one of the Th1 prototypical cytokines and often co-secreted with IL-22. However 
the possible interplay of IL-22 and IFN-γ has not been systematically investigated. 
 
IFN-γ can lead to the upregulation of MHC-I, MHC-II and ICAM-1 in epithelial cells thus 
enhancing adhesion of CD4+ and CD8+ T cells and apoptosis induction in epithelial cells 
affected (Miyahara et al, 2004; Pennino et al, 2010; Schwarze et al, 1999; Traidl et al, 
2000). IL-22 can antagonize IFN-γ-induced MHCI, MHCII and CD54-intercellular 
adhesion molecule upregulation in bronchial epithelial cells indicating a regulatory 
function of IL-22 in the context of IFN-γ-induced inflammation (Pennino et al, 2013). 
These findings led us to hypothesize that IL-22 may also affect the regulation of other 
proteins such as chemokines. 
 
IFN-γ induces chemokines in epithelial cells such as colorectal cancer cells. In the 
intestinal mucosa, intestinal epithelial cells are an important source of chemokines. The 
observed CCL22 upregulation in HT29 upon IFN-γ stimulation is consistent with 
published data (Berin et al, 2001).  
 
In the intestinal mucosa, multiple immune cells are capable of producing IFN-γ: B and T 
lymphocytes, mononuclear phagocytes, and dendritic cells, as well as smaller numbers 
of eosinophils and mast cells (Berin et al, 2001). We hypothesized that IL-22 might play 
a role in the tumor microenvironment by regulating chemokine expression in tumor cells. 
In our experiments, IL-22 did impair IFN-γ-induced chemokine release for CCL22 in 
HT29 cells. 
 
Our findings suggest that IL-22 can inhibit some effects of IFN-γ. Induction of CCL22 in 
the tumor microenvironment can lead to the attraction of CCR4-positive immune cells 
such as Th-17 cells, Th-22 and Tregs. Further, Th-17 cells are attracted by CCL22 and 
their signature cytokine IL-17 exerts an inflammatory and protumorigenic role (He et al, 
2012; Hyun et al, 2012). Th-22 cells also express CCR4 and produce mainly IL-22 
(Duhen et al, 2009) and IL-22 can exert a protumorigenic role itself. The inhibition of 
CCL22 expression by IL-22 in this case would lead to less attraction of these cells and 
thus to an antitumor response. 
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However, Tregs play a crucial role during the control of antitumor immune responses.  
Tregs can produce immunosuppressive cytokines such as IL-10, TGF-ß and IL-35 
(Nishikawa & Sakaguchi, 2010). Thus by inhibiting CCL22 secretion, IL-22 may reduce 
the attraction of immunosuppressive Tregs and thus exert a protumorigenic function. 
 
IFN-γ upregulated IL-22-R1 in HT29 cells. This finding is supported by a study where 
keratinocytes upregulated IL-22-R1 upon IFN-γ (Kunz et al, 2006). 
 
 
6.4.1.1. IL-22 and TNF-α synergistically induce CCL22 and in HT29 cells 
 
We next investigated whether IL-22 can interfere with the TNF-α pathway in colorectal 
cancer cells. This is of particular importance, as these two cytokines are co-secreted by 
Th-22 cells (Eyerich et al, 2009).  
 
TNF-α is a cytokine with well-described anti-cancer effects and has been used in anti-
cancer therapy for patients suffering from solid tumors (Bertazza & Mocellin, 2010). 
However, in the recent years a dual role of TNF-α has been described, as this cytokine 
is also capable of driving tumor elimination (Lebrec et al, 2015). In colorectal cancer it 
has been reported that TNF-α might play a tumor-promoting role (Grivennikov & Karin, 
2011). 
 
For HT29 cells, TNF-α highly upregulates CCL22 (Berin et al, 2001) which is consistent 
with our data, showing upregulation of CCL22 by TNF-α on mRNA level. Addition of IL-
22 to TNF-α on tumors cells led to a functional synergism of TNF-α and IL-22: the 
combination lead to upregulation of CCL22 in HT29 cells. As mentioned above, CCL22 
is a chemokine that is a chemoattractant for Tregs and may thus anti-cancer immune 
responses. 
 
So far, few studies investigated the functional interplay of IL-22 and TNF-α. Eyerich et 
al., could demonstrate that TNF-α and IL-22 synergistically induce an innate immune 
profile in human keratinocytes including IP10, CXCL12 and HBD-2 (Eyerich et al, 2011). 
This synergism is mediated by the MAP kinase p38.   
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IL-22-R1 in both keratinocytes and dermal fibroblasts is induced by TNF-α (Wolk et al, 
2009; Wolk et al, 2004). These data strengthen our finding that TNF-α upregulates IL-22-
R1 in HT29 cells. By upregulating IL-22-R1 on tumor cells, these cells become more 
sensitive to IL-22 and thus the synergistic effect of TNF-α and IL-22 might be enhanced.  
 
 
6.5. Conclusion and perspectives 
 
Since IL-22 plays a crucial role in inflammation and proliferation, it might have promise 
as a potential therapeutic for different cancer entities including colorectal cancer. Our 
data that IL-22 has an impact on colorectal cancer cells promotes the idea that IL-22-
targeting may be a reasonable strategy for cancer therapy. As IL-22 does not act on 
immune cells itself, modulation of the IL-22/IL-22-R1 axis may have a different safety 
profile than the targeting of other cytokine pathways which than have profound immune 
suppressive effects. 
 
Neutralizing antibodies could target IL-22. IL-22 neutralizing antibodies are being tested 
in autoimmune disorders such as psoriasis and RA 
(https://clinicaltrials.gov/ct2/show/NCT01941537). On the other hand, blockade of 
chemokines that attract IL-22 producing T cells such as CCL20 may diminish the impact 
of IL-22 on the tumor milieu.  
 
Since the data presented here only touches on the biology of IL-22 further studies will be 
needed to better understand the role of IL-22 in cancer genesis and progression. 
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8.  Appendices 
8.1.  Abbreviations 
 
AHR     Aryl hydrocarbon receptor 
APC      Allophycocyanin 
 
BSA      Bovine serum albumin 
 
CCR     Chemokine receptor 
CCL     Chemokine ligand  
CD     Custer of differentiation 
cDNA      Complementary deoxyribonucleic acid 
 
DMSO     Dimethyl sulfoxide 
DMEM     Dulbecco's modified Eagle´s medium 
DNA      Deoxyribonucleic acid 
DTT     Dithiothreitol 
 
EDTA      Ethylene diamine tetraacetic acid 
ELISA      Enzyme-linked immunosorbent assay 
 
 
FACS      Fluorescence-activated cell sorting 
FITC      Fluorescein isothiocyanate 
 
 
HPRT     Hypoxanthine phosphoribosyltransferase 
HRP      Horseradish peroxidase 
h     Hours 
 
 
IFN     Interferon 
Ig      Immunoglobulin 
IL     Interleukin 
IL-22BP     IL-22 binding protein 
IL-10-R2    IL-10 receptor-2 
IL-22-R1    IL-22 receptor-1  
IBD     Inflammatory bowel disease 
   
 
JAK      Janus kinase 
 
 
LTi      Lymphoid tissue inducer 
LTi-like     Lymphoid tissue-like inducer 
 
 
mRNA     Messenger ribonucleic acid 
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NK cells    Natural killer cells 
NKT cell    Natural killer T cell  
 
O 
 
PBS      Phosphate-buffered saline 
PBMC     Peripheral blood mononuclear cells  
pDC     Plasmacytoid dendritic cell 
PE     Phycoerythrin 
PerCP     Peridinin chlorophyll protein 
PI     Propidium iodide  
PVDF      Polyvinylidene fluoride  
 
 
qRT-PCR     Quantitative reverse transcription polymerase  
     chain reaction 
 
RA     Rheumatoid arthritis 
RNA     Ribonucleic acid 
RORγt     Retinoic-acid-related orphan nuclear receptor  
RPMI     Roswell Park Memorial Institute 
RT      Room temperature 
RT-PCR    Reverse transcription polymerase chain reaction  
 
 
SDS     Sodium dodecyl sulfate 
SDS-PAGE    Sodium dodecyl sulfate polyacrylamide gel   
     electrophoresis 
SEM     Standard error of the mean 
SH2     Sarcoma homology 2 
STAT      Signal transducer and activator of transcription 
 
 
TGF-β     Transforming growth factor-β 
Th     T helper 
TNF      Tumor necrosis factor 
TYK2     Tyrosine kinase 2 
 
 
 
 
 
 
 
 
 
 
 
 
  
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
 
 71 
8.2.  Publications 
Work performed during my doctoral thesis 
 
1. Kobold S, Volk S, Clauditz T, Küpper NJ, Minner S, Tufman A, Duwell P, 
Lindner M, Koch I, Heidegger S, Rothenfuer S, Schnurr M, Huber RM, Wilczak W, 
Endres S (2013). Interleukin-22 is frequently expressed in small- and large-cell lung 
cancer and promotes growth in chemotherapy-resistant cancer cells. 
J Thorac Oncol 8: 1032-1042 
 
Work performed prior to doctoral thesis: 
 
1. Muller AM, Poyser J, Küpper NJ, Burnett C, Ko RM, Kohrt HE, Florek M, Zhang 
P, Negrin RS, Shizuru JA (2014). Donor hematopoiesis in mice following total lymphoid 
irradiation requires host T-regulatory cells for durable engraftment. 
Blood 123: 2882-2892 
 
2. Retzlaff M, Rohrberg J, Küpper NJ, Lagleder S, Bepperling A, Manzenrieder F, 
Peschek J, Kessler H, Buchner J (2013). The regulatory domain stabilizes the p53 
tetramer by intersubunit contacts with the DNA binding domain. 
J Mol Biol 425: 144-155 
  
3. Muller AM, Shashidhar S, Küpper NJ, Kohrt HE, Florek M, Negrin RS, Brown 
JM, Shizuru JA (2012). Co-transplantation of pure blood stem cells with antigen-specific 
but not bulk T cells augments functional immunity. 
Proc Natl Acad Sci U S A 109: 5820-5825 
 
 
Abtracts 
1. Küpper NJ, Völk S, Ochs C, Clauditz T, Minner S, Tufman A, Düwell P, Lindner 
M, Koch I, Heidegger S, Rothenfußer S, Schnurr M, Huber RM, Wilczak W, 
Endres S, Kobold S (2013). 
Interleukin-22 is frequently expressed in small and large cell lung cancer and promotes 
growth inchemotherapy resistant cancer cells. 
3rd Munich Lung Conference 2013 – International DZL Symposium (poster presentation), 
Munich, Germany 
 
2.   Völk S, Küpper NJ, Clauditz T, Minner S, Tufman A, Düwell P, Lindner M, Koch 
I, Merk M, Rothenfußer S, Schnurr M, Huber R, Sauter G, Wilczak W, Endres S, Kobold 
S (2012). 
Expression and impact of interleukin-22 in human lung cancer.  
CIMT 2012 (poster presentation), Mainz, Germany  
 
3. Tufman A, Huber RM, Völk S, Edelmann M, Gamarra F, Kiefl R, Küpper NJ, 
Tian F, Endres S, Kobold S (2012). 
Bestimmung von Interleukin-22 in broncheoalveolärer Lavage (BAL) und 
endobronchialer Spülflüssigkeit von Patienten mit und ohne Lungenkarzinom – eine 
Machbarkeitsstudie. 
DGIM 2012 (talk), Wiesbaden, Germany 
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
 
 72 
Oral presentations 
1. Küpper NJ. Polarisierung von Th-22 in peripheren Blut mononukleären Zellen.  
4th Annual Post-Doc Workshop, Evia, Greece, 2012 
 
2. Küpper NJ. Rolle und zelluläre Quellen von Interleukin-22 in 
Tumorerkrankungen. SYMPOSIUM GENTIANUM, Fünfzehnte Klausurtagung der 
Medizinischen Klinik  und Poliklinik IV Klinikum der Universität München, 
Frauenchiemsee, Germany, 2013 
 
3. Küpper NJ. Impact of IL-22 on colon cancer. 
 8th Annual Retreat, Graduiertenkolleg 1202 Oligonucleotides in cell biology and 
therapy, Ohlstadt, Germany, 2013 
 
  
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
 
 73 
8.3.  Acknowledgements 
 
First I would like to thank my Doktorvater Professor Dr. med. Stefan Endres for his 
commitment and support during the time of my doctoral thesis. Thank you, Stefan, your 
enthusiasm and support for the Klin-Pharm are beyond all description. 
 
PD Dr. med. Sebastian Kobold I would like to thank for his patience and support as well 
as for the supervision of my thesis. His input, professional experience and leadership of 
our group were always a great help. 
 
Conny Voigt and Vicky Blumenberg, you were the best colleagues I could have imagined 
for personal and scientific discussions. 
 
Special thanks to the people of Room 2 (Dr. Friederike Saathoff, Dr. Tina Adunka, Dr. 
Melanie Merk, Dr. Christian Wißkirchen, Dr. Christoph Freier, Dr. Gabriele Wiedemann 
and Dr. Moritz Rapp). 
 
Thanks to my group „AG Kobold and Endres”: Julius Steffen, Stefanie Völk, Luisa Hofer, 
Luisa Berdin, Philip Peters, Christopher Lampert, Michael Chaloupka, Simon 
Grassmann, Daniel Wenk and Susanne Wenk. 
 
I thank Dr. Michael Hristov for answering all my questions concerning FACS analysis. 
 
I thank Dr. Jens Neumann for the patient samples and the good collaboration. 
 
Special thanks to Michael Pirzas for support. 
 
I am deeply thankful to Michael Becker for his patience, support and motivation. 
 
Many thanks to the Klin-Pharm and all Grako members. 
 
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
 
 74 
Eidesstattliche Versicherung  
 
 
Küpper, Natascha Jennifer 
 
 
Ich erkläre hiermit an Eides statt,  
dass ich die vorliegende Dissertation mit dem Thema  
 
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer 
 
selbständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient 
und alle Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, 
als solche kenntlich gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle  
einzeln nachgewiesen habe.  
 
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in  
ähnlicher Form bei einer anderen Stelle zur Erlangung eines akademischen Grades  
eingereicht wurde.  
 
 
Ort, Datum     Unterschrift Doktorandin/Doktorand 
 
 
 
 
 
 
